Trial Information
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Inclusion Criteria:
- Patients with diagnosis of advanced RCC and decision taken by the investigator to
prescribe Sorafenib
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Tumor status
Outcome Time Frame:
After about 3, 6, 9 and 12 months
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Study ID:
14686
NCT ID:
NCT00895674
Start Date:
July 2006
Completion Date:
August 2010
Related Keywords:
- Carcinoma, Renal Cell
- Carcinoma, Renal Cell (Advanced)
- Advanced Renal Cell Carcinoma
- Carcinoma
- Carcinoma, Renal Cell